Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.

Protect your retirement savings from the inevitable devaluation of the dollar…

Paul Stone Biography and Net Worth

CFO of IDEAYA Biosciences

Paul is a life science executive with over 20 years of legal, financial, and management experience. Paul was previously with 5AM Ventures for over nine years in various leadership capacities including as Partner, General Counsel, and Chief Operating Officer. Paul serves as a Board of Director of Scientist.Com and was a founding Director at Cidara (NASDAQ: CDTX), Homology (NASDAQ: FIXX), and IDEAYA (NASDAQ: IDYA), as well was a Board Observer at RareCyte and other companies. He also held early management and operating rolls at Cidara, Entrada, IDEAYA and Homology. Prior to joining 5AM, Paul was Senior Vice President and General Counsel at Ethos Pharmaceuticals, Senior Vice President, General Counsel and Chief Patent Counsel at Ilypsa (acquired by Amgen) and Vice President, Chief Patent Counsel at Symyx (IPO). He earlier served in roles at Boeing and Wisconsin Electric.

Paul earned a B.S. in Chemical Engineering, University of Wisconsin, Madison, after which he served as a U.S. Naval Officer on USS NIMITZ. He received a J.D. from University of Wisconsin Law School and practiced intellectual property law as a Patent Attorney at Senniger Powers. Paul taught patent law, trade secrets law and licensing as an adjunct professor at University of Missouri and Santa Clara University. He also served on the Board of Directors of a regional non-profit, Save the Bay.

What is Paul A. Stone's net worth?: The estimated net worth of Paul A. Stone is at least $386,167.53 as of August 29th, 2023. Mr. Stone owns 9,303 shares of IDEAYA Biosciences stock worth more than $386,168 as of April 16th. This net worth approximation does not reflect any other investments that Mr. Stone may own. Learn More about Paul A. Stone's net worth.
How do I contact Paul A. Stone?: The corporate mailing address for Mr. Stone and other IDEAYA Biosciences executives is 7000 SHORELINE COURT SUITE 350, SOUTH SAN FRANCISCO CA, 94080. IDEAYA Biosciences can also be reached via phone at (650) 443-6209 and via email at [email protected]. Learn More on Paul A. Stone's contact information.
Has Paul A. Stone been buying or selling shares of IDEAYA Biosciences?: Paul A. Stone has not been actively trading shares of IDEAYA Biosciences during the last quarter. Most recently, Paul A. Stone sold 5,000 shares of the business's stock in a transaction on Tuesday, August 29th. The shares were sold at an average price of $28.87, for a transaction totalling $144,350.00. Following the completion of the sale, the chief financial officer now directly owns 9,303 shares of the company's stock, valued at $268,577.61. Learn More on Paul A. Stone's trading history.
Who are IDEAYA Biosciences' active insiders?: IDEAYA Biosciences' insider roster includes Michael Dillon (SVP), Yujiro Hata (CEO), Andres Ruiz Briseno (Senior Vice President, Head of Finance and Investor Relations), Paul Stone (CFO), and Jason Throne (insider). Learn More on IDEAYA Biosciences' active insiders.
Are insiders buying or selling shares of IDEAYA Biosciences?: In the last twelve months, insiders at the sold shares 21 times. They sold a total of 219,474 shares worth more than $8,035,837.19. The most recent insider tranaction occured on February, 9th when CEO Yujiro S Hata sold 23,557 shares worth more than $1,072,785.78. Insiders at IDEAYA Biosciences own 5.1% of the company. Learn More about insider trades at IDEAYA Biosciences.
Information on this page was last updated on 2/9/2024.

Paul A. Stone Insider Trading History at IDEAYA Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/29/2023	Sell	5,000	$28.87	$144,350.00	9,303
8/21/2023	Sell	978	$26.40	$25,819.20	14,303
8/18/2023	Sell	3,822	$26.38	$100,824.36	15,281
8/16/2023	Sell	200	$26.43	$5,286.00	19,103
8/9/2023	Sell	2,500	$25.05	$62,625.00	19,303
9/7/2021	Sell	2,500	$27.42	$68,550.00	12,944
6/17/2020	Sell	3,100	$17.97	$55,707.00	18,100
5/28/2019	Buy	250,000	$10.00	$2,500,000.00

Paul A. Stone Buying and Selling Activity at IDEAYA Biosciences

IDEAYA Biosciences Company Overview

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Today's Range

Now: $41.17

$40.81

$42.05

50 Day Range

MA: $44.29

$41.40

$47.13

2 Week Range

Now: $41.17

$13.81

$47.74

Volume

404,758 shs

Average Volume

860,916 shs

Market Capitalization

$3.07 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8

Trump’s “Tax Free” Retirement Strategy

From Gold Safe Exchange | Ad